<SEC-DOCUMENT>0001172661-25-003249.txt : 20250814
<SEC-HEADER>0001172661-25-003249.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814080103
ACCESSION NUMBER:		0001172661-25-003249
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enliven Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001672619
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				811523849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91465
		FILM NUMBER:		251214450

	BUSINESS ADDRESS:	
		STREET 1:		6200 LOOKOUT ROAD
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		720-647-8519

	MAIL ADDRESS:	
		STREET 1:		6200 LOOKOUT ROAD
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IMARA Inc.
		DATE OF NAME CHANGE:	20160419

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Polar Capital Holdings Plc
		CENTRAL INDEX KEY:			0001837309
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		16 PALACE STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			SW1E 5JD
		BUSINESS PHONE:		02072272700

	MAIL ADDRESS:	
		STREET 1:		16 PALACE STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			SW1E 5JD
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Polar Capital Holdings Plc -->
          <cik>0001837309</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, $0.001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>06/30/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001672619</issuerCik>
        <issuerName>ENLIVEN THERAPEUTICS, INC.</issuerName>
        <issuerCusip>29337E102</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>6200 Lookout Road</com:street1>
          <com:city>Boulder</com:city>
          <com:stateOrCountry>CO</com:stateOrCountry>
          <com:zipCode>80301</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Polar Capital Holdings Plc</reportingPersonName>
      <citizenshipOrOrganization>X0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2536881.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2536881.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2536881.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.17</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Polar Capital LLP</reportingPersonName>
      <citizenshipOrOrganization>X0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2536881.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2536881.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2536881.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.17</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Polar Capital Funds PLC - Biotechnology Fund</reportingPersonName>
      <citizenshipOrOrganization>X0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2536881.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2536881.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2536881.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.17</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>ENLIVEN THERAPEUTICS, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>6200 Lookout Road, Boulder, CO 80301</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Polar Capital Holdings Plc

Polar Capital LLP

Polar Capital Funds PLC - Biotechnology Fund</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>16 Palace Street
London, SW1E 5JD

George's Court, 54-62 Townsend Street
Dublin 2, Ireland</principalBusinessOfficeOrResidenceAddress>
        <citizenship>United Kingdom</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>2,536,881</amountBeneficiallyOwned>
        <classPercent>5.17%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>2,536,881</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>2,536,881</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0

Based on 49,069,258 shares outstanding as reported in the Issuer's Form 10-Q on May 14, 2025.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>Information for each Subsidiary is incorporated on the respective cover pages.</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>Exhibit I

JOINT FILING STATEMENT

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Polar Capital Holdings PLC
By: /s/ Nicholas Farren
Name: Nicholas Farren
Title: Chief Operating Officer

Polar Capital LLP
By: /s/ Nicholas Farren
Name: Nicholas Farren
Title: Chief Operating Officer

Polar Capital Funds PLC - Biotechnology Fund
By: /s/ Nicholas Farren
Name: Nicholas Farren
Title: Chief Operating Officer</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Polar Capital Holdings Plc</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Nicholas Farren</signature>
        <title>Nicholas Farren - Chief Operating Officer</title>
        <date>08/14/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Polar Capital LLP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Nicholas Farren</signature>
        <title>Nicholas Farren - Chief Operating Officer</title>
        <date>08/14/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Polar Capital Funds PLC - Biotechnology Fund</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Nicholas Farren</signature>
        <title>Nicholas Farren - Chief Operating Officer</title>
        <date>08/14/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
